JP2024502446A5 - - Google Patents
Info
- Publication number
- JP2024502446A5 JP2024502446A5 JP2023541058A JP2023541058A JP2024502446A5 JP 2024502446 A5 JP2024502446 A5 JP 2024502446A5 JP 2023541058 A JP2023541058 A JP 2023541058A JP 2023541058 A JP2023541058 A JP 2023541058A JP 2024502446 A5 JP2024502446 A5 JP 2024502446A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- composition according
- compound
- lung cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135449P | 2021-01-08 | 2021-01-08 | |
| US63/135,449 | 2021-01-08 | ||
| US202163189625P | 2021-05-17 | 2021-05-17 | |
| US63/189,625 | 2021-05-17 | ||
| PCT/US2022/011673 WO2022150628A1 (en) | 2021-01-08 | 2022-01-07 | Use of a kras g12c inhibitor in treating cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502446A JP2024502446A (ja) | 2024-01-19 |
| JP2024502446A5 true JP2024502446A5 (cg-RX-API-DMAC7.html) | 2025-01-15 |
Family
ID=80222156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541058A Pending JP2024502446A (ja) | 2021-01-08 | 2022-01-07 | 癌の治療におけるkras g12c阻害剤の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240091230A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4274579A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024502446A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022205969A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3206523A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023007918A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI906448B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022150628A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA127968C2 (uk) | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| EP3738593A1 (en) * | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| EP3972973A1 (en) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Solid state forms |
-
2022
- 2022-01-07 WO PCT/US2022/011673 patent/WO2022150628A1/en not_active Ceased
- 2022-01-07 MX MX2023007918A patent/MX2023007918A/es unknown
- 2022-01-07 TW TW111100657A patent/TWI906448B/zh active
- 2022-01-07 EP EP22703115.0A patent/EP4274579A1/en not_active Withdrawn
- 2022-01-07 US US18/270,581 patent/US20240091230A1/en active Pending
- 2022-01-07 CA CA3206523A patent/CA3206523A1/en active Pending
- 2022-01-07 JP JP2023541058A patent/JP2024502446A/ja active Pending
- 2022-01-07 AU AU2022205969A patent/AU2022205969A1/en active Pending
- 2022-01-07 EP EP25206294.8A patent/EP4650006A3/en active Pending